Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Carfilzomib (CFZ) is a proteasome inhibitor currently approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Multiple trials are ongoing to evaluate its efficacy and safety in newly diagnosed multiple myeloma (NDMM). The use of CFZ-based two- or three-drug combination regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Imtiaz, Hassaan, Khan, Maimoona, Ehsan, Hamid, Wahab, Ahsan, Rafae, Abdul, Khan, Ali Y, Jamil, Abdur, Sana, Muhammad Khawar, Jamal, Abdullah, Ali, Taimoor Jaffar, Ansar, Iqraa, Khan, Muzammil M, Khouri, Jack, Anwer, Faiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493667/
https://www.ncbi.nlm.nih.gov/pubmed/34629878
http://dx.doi.org/10.2147/OTT.S317570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493667/
https://www.ncbi.nlm.nih.gov/pubmed/34629878
http://dx.doi.org/10.2147/OTT.S317570

Ejemplares similares